GH Research PLC

NASDAQ:GHRSUnited States

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.

Contact Information

Headquarters

Joshua Dawson House, Dawson StreetDublin, Ireland D02 RY95

Phone

---

Fax

---

Executives

Non-Executive Chairman of the Board

Florian Schonharting

Chief Medical Officer

Velichka Valcheva

Non-Executive Independent Vice Chairman of the Board

Michael Forer

Vice President - Finance

Julie Ryan

Managing Director, Ireland

Magnus Halle